
Bristol Myers Squibb & Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.
- BMY shares are climbing with conviction. See the market dynamics here.

Bristol Myers Squibb & Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.